Sterling Capital Management’s Corcept Therapeutics CORT Stock Holding History
Bought
Maintained
Sold
Other funds holding CORT
Sterling Capital Management's CORT Position: Q3 2026 in Review
Sterling Capital Management reduced its Corcept Therapeutics (CORT) stake by 65% in Q3 2026, selling an estimated $44.1K and leaving 216 shares worth $24.9K. The position accounts for ﹤0.01% of the portfolio, ranked #2087.
Sterling Capital Management first reported a position in CORT in Q3 2019 and has held it in 10 quarters since. The position peaked at $1.17M in Q3 2019. 503 funds tracked by Wall St. Rank hold CORT as of Q3 2026.
- Sterling Capital Management held 216 shares of Corcept Therapeutics worth $24.9K as of Q3 2026.
- Sterling Capital Management sold 410 Corcept Therapeutics shares in Q3 2026, an estimated $44.1K.
- Corcept Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q3 2026, its #2087 holding.
- Sterling Capital Management first reported a position in Corcept Therapeutics in Q3 2019 and has held it in 10 quarters since.
- Sterling Capital Management's Corcept Therapeutics position peaked at $1.17M in Q3 2019.
- 503 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2026.
Based on Sterling Capital Management's 13F filing for Q3 2026, filed 22 Oct 2026.